Serum IGF‐I concentration was positively associated with prostate cancer incidence (HR per 5 nmol/L increment = 1.09, 95% CI 1.05‐1.12; Ptrend < .0001, Figure 1) and prostate cancer mortality (HR per 5 nmol/L increment =1.15, 95% CI 1.02‐1.29; Ptrend = .03, Figure 2). Here, IGF1 is linked to prostate carcinoma.